Votrient for breast cancer – pro
Votrient(pazopanib) is a multi-targeted tyrosine kinase inhibitor and it is currently approved for renal cell carcinoma. VOTRIENT® is indicated for the treatment of patients with advanced renal cell carcinoma(RCC). Preclinical data show the anti-tumor activity of pazopanib in animal models. There have been some phase II trials of this drug for breast cancer. These studies suggest that Votrient provides disease stability in advanced breast cancer. The activity seen is comparable with that of other antiangiogenic agents in this setting. However, it s still being studied: for example, there is a trial NCT00509587, Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer.
S.K.Taylor etal, A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium.
A. Kordestani et al, Pazopanib for the treatment of breast cancer.Expert Opin Investig Drugs. 2012 Feb;21(2):217-25
Fiona Tsui-Fen Cheng et al, Pazopanib Sensitivity in a Patient With Breast Cancer and FGFR1 Amplification. J Natl Compr Canc Netw 2017;15:1456-1459